Latest Regulatory Challenges News

Elanor Funds Management has lodged an application with the Takeovers Panel contesting disclosure deficiencies in Lederer’s takeover bid for Elanor Commercial Property Fund. The dispute centers on transparency around ownership, management, and strategic intentions.

IMEXHS Limited reported steady revenue growth and a strategic push to scale its SaaS medical imaging platform, while navigating margin challenges and regulatory risks in Colombia.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

betr Entertainment has lodged a formal application with the Takeovers Panel, contesting PointsBet’s board decision to accelerate vesting of performance rights amid competing takeover bids, a move that significantly boosted MIXI’s voting power.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

The Star Entertainment Group reported a $471.5 million net loss for FY25, marking a 72% improvement from the prior year but underscored by ongoing regulatory challenges and a complex joint venture exit.

Evolution Energy Minerals has disclosed a default notice from Tanzanian regulators over delayed mining commencement, yet remains confident in retaining its key graphite mining license.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.